Remdesivir Approved to Treat COVID-19 Amid Controversy.

Aschenbrenner, Diane S

Aschenbrenner, Diane S.

Aschenbrenner DS; Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: daschenbrenner@ndm.edu.

Am J Nurs ; 121(1): 22-24, 2021 01 01.

Article in English | MEDLINE | ID: covidwho-990815

ABSTRACT

ABSTRACT

Remdesivir (Veklury) is the first antiviral drug approved to treat patients ages 12 and older who are hospitalized with COVID-19.The drug is administered via slow IV infusion.Elevated liver enzymes are common with treatment. Hypersensitivity reactions, including anaphylaxis, are possible.

Subject(s)

Adenosine Monophosphate/analogs & derivatives; Alanine/analogs & derivatives; Antiviral Agents/therapeutic use; COVID-19 Drug Treatment; Adenosine Monophosphate/therapeutic use; Alanine/therapeutic use; Clinical Trials as Topic; Drug Approval; Humans; United States; United States Food and Drug Administration

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Adenosine Monophosphate / Alanine / COVID-19 Drug Treatment Type of study: Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: North America Language: English Journal: Am J Nurs Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google